Overview

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis
Phase:
Phase 3
Details
Lead Sponsor:
Almirall, S.A.
Collaborators:
Almirall Hermal GmbH
Harrison Clinical Research
Treatments:
Dimethyl Fumarate